Eli Lilly and Company (India) Pvt. Ltd. has launched Lormalzi (donanemab, 350 mg/20 mL IV vial) in India following marketing authorisation from the Central Drugs Standard Control Organization (CDSCO) for the treatment of Alzheimer’s disease in patients with mild cognitive impairment or those in the mild dementia stage of the disease.

According to the company, Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence demonstrating the potential for treatment optimisation based on amyloid reduction.

Winselow Tucker, President and General Manager, Eli Lilly and Company (India) said, “The launch of Lormalzi in India reflects our longstanding commitment to advancing innovation and supporting evidence-based intervention for people living with Alzheimer’s disease in India. We are committed to strengthening patient access by collaborating closely with stakeholders across the healthcare ecosystem, including industry, government, payers, healthcare systems, and advocacy organisations, to raise awareness and address barriers to diagnosis and treatment.” 

Rahul Kapur, Senior Director, Medical, Eli Lilly and Company (India), said, “Lormalzi is supported by robust clinical evidence targeting amyloid pathology, a key feature of the disease process. Its availability in India represents an important step forward in advancing evidence-based care for eligible patients with early symptomatic Alzheimer’s disease. Early diagnosis, supported by appropriate patient assessment, remains central to enabling informed, evidence-led treatment decisions.”